Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) : A Brief Report on Emerging Data

© 2020 Beziat and Ysebaert..

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes. CD123, the α-subunit of interleukin (IL)-3 receptor, is constantly overexpressed at the surface of tumoral cells. Tagraxofusp (or SL-401) is a recombinant cytotoxin which consists of human interleukin-3 fused to a truncated diphtheria toxin. It is currently the only novel therapy with a prospective evaluation of efficacy and safety in the treatment of BPDCN and is also the only one to achieve FDA approval. In this short review, the results of tagraxofusp are summarized and perspectives of its use in BPDCN and in other malignancies are discussed. The safety profile is also summarized, since capillary leak syndrome is the main toxic effect of the drug, along with more common toxicities including an increase in transaminases and thrombocytopenia.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:13

Enthalten in:

OncoTargets and therapy - 13(2020) vom: 01., Seite 5199-5205

Sprache:

Englisch

Beteiligte Personen:

Beziat, Guillaume [VerfasserIn]
Ysebaert, Loïc [VerfasserIn]

Links:

Volltext

Themen:

Blastic plasmacytoid dendritic cell neoplasm
CD123
Journal Article
Review
SL-401
Targeted therapy

Anmerkungen:

Date Revised 28.09.2020

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.2147/OTT.S228342

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM31184684X